One analyst is now more bullish about this clinical-stage biotech stock. Shares of Nkarta (NKTX 1.61%) were soaring 11.1% as of 11:07 a.m. ET on Wednesday. The big gain came after Raymond James upgraded the stock from outperform to a strong buy and maintained its 12-month price target at $16. This analyst upgrade came after Nkarta provided its second-quarter update on Tuesday. The clinical-stage biopharmaceutical company expects to begin patient enrollment by year-end in an Ntrust-2 clinical trial evaluatin ...

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 Cash balance of $426.7 million on June 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored ...

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 Cash balance of $426.7 million on June 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-sta ...

Core Insights - Nkarta, Inc. has announced the initiation of an investigator-sponsored trial (IST) for NKX019, a CAR NK-cell therapy targeting CD19, in patients with systemic lupus erythematosus (SLE) [1][2] - The IST aims to expand the clinical evaluation of NKX019, following the initiation of the Phase 1 clinical trial Ntrust-1 for lupus nephritis [1][2] Company Overview - Nkarta is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf NK cell therapies [5] - The company utilizes a combination of cell expansion, cryopreservation, and proprietary cell engineering technologies to create a pipeline of NK cell therapies [5] Clinical Trial Details - The Phase 1 IST is being conducted at Columbia University Irving Medical Center and will enroll up to 6 patients with SLE [2] - The trial will assess safety and clinical outcomes, including translational and biomarker studies [2] - Patients will receive NKX019 on Days 0, 7, and 14 after lymphodepletion with cyclophosphamide [2] NKX019 Characteristics - NKX019 is an allogeneic, cryopreserved immunotherapy candidate engineered with a humanized CD19-directed CAR and a membrane-bound form of interleukin-15 (IL-15) [4] - The therapy aims to provide enhanced cell targeting and greater persistence without the need for exogenous cytokine support [4]

"This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as we embark on groundbreaking clinical trials and expand our footprint in multiple autoimmune disease settings. These executive changes are expected to significantly enhance our ability to accelerate the development and ultimate commercialization of pioneering NK cell therapies for patients that need them," said Paul J. Hastings, CEO of Nkarta. "I am thrilled to have Nadir, a trusted thought partner of many ye ...

Nkarta, Inc. (NKTX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy becau ...

For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan. For example, these businesses have proven to be skilled in cost control. This is essential for maintaining profitability even in the face of declining sales. Meanwhile, they demonstrate strong cash flow generation and deliberate cybersecurity expansions, strengthening their position in the in ...

Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis NKX019 is an allogeneic, off-the-shelf, chimeric antigen receptor (CAR) NK-cell therapy candidate engineered to deplete CD19-positive cells in B-cell mediated disease. The approach leverages the potential advantages of NK cell therapy, including fludarabine-free lymphodepletion to reduce toxicity, deep and rapid B-cell depletion, and the added utility of on-demand ...

Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis SOUTH SAN FRANCISCO, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the initiation of Ntrust-1, a multi-center clinical trial of NKX019 in lupus nephritis, with the first patient in screening. The company also announced the clearance by the ...

He previously held R&D leadership roles as Senior Vice President of Translational Science and Medicine, Immunology at Janssen Pharmaceuticals, Executive Global Program Head of the Immunology and Dermatology Franchise at Novartis, as well as a Translational Medicine Leader at Roche and a Group Director at Bristol Meyers Squibb. Cautionary Note on Forward-Looking Statements SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company de ...